Table 4.
Percent decreases in bone turnover markers after 48 weeks of treatment with risedronate according to the number of comorbidities
| Number of complications | ||||
|---|---|---|---|---|
| 0 | 1 | 2 | 3 | |
| NTX | ||||
| N | 341 | 280 | 95 | 10 |
| Decrease rate (%) | 35.8 ± 34.4 | 34.7 ± 43.2 | 36.1 ± 34.8 | 34.4 ± 35.9 |
| Difference | 0 | −1.1 | 0.3 | −1.4 |
| 95 % confidence interval | – | −7.3–5.0 | −7.6–8.1 | −23.1–20.3 |
| CTX | ||||
| N | 182 | 185 | 59 | 7 |
| Decrease rate (%) | 55.8 ± 29.4 | 53.4 ± 40.4 | 58.6 ± 21.2 | 64.8 ± 13.3 |
| Difference | 0 | −2.4 | 2.8 | 9.0 |
| 95 % confidence interval | – | −9.7–4.9 | −5.3–11.0 | −13.0–31.1 |
| BAP | ||||
| N | 181 | 185 | 59 | 7 |
| Decrease rate (%) | 35.4 ± 19.5 | 33.0 ± 22.6 | 31.9 ± 17.0 | 29.4 ± 21.8 |
| Difference | 0 | −2.4 | −3.5 | −6.0 |
| 95 % confidence interval | – | −6.8–2.0 | −9.1–2.1 | −20.8–8.9 |
NTX N-terminal telopeptide of type 1 collagen, CTX C-terminal telopeptide of type 1 collagen, BAP bone-specific alkaline phosphatase